Molecular profiling of breast cancer
- PMID: 24882344
- DOI: 10.1016/j.soc.2014.03.004
Molecular profiling of breast cancer
Abstract
Breast cancer is now considered a heterogeneous and phenotypically diverse disease. Molecular profiling is used in clinical practice in 2 broad categories: (1) characterization of breast cancers beyond the standard histopathologic features such as tumor grade, histologic subtype, and biomarker profile for prognostic information; and (2) prediction of response to therapy and clinical outcome. This article addresses the importance and application of molecular subtype analysis, and provides an in-depth analysis of the clinical application of the molecular prognostic indices for ductal carcinoma in situ, node-negative invasive breast cancer, and node-positive invasive breast cancer.
Keywords: Breast cancer; Genome; Molecular diagnostics; Molecular profiling; Prognostication.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.Breast Cancer Res. 2005;7(1):R119-29. doi: 10.1186/bcr963. Epub 2004 Nov 23. Breast Cancer Res. 2005. PMID: 15642160 Free PMC article.
-
Molecular profiling for DCIS.Clin Adv Hematol Oncol. 2014 Sep;12(9):611-3. Clin Adv Hematol Oncol. 2014. PMID: 25654484 No abstract available.
-
Ductal carcinoma in situ: a review of recent advances.Curr Opin Obstet Gynecol. 2007 Feb;19(1):63-7. doi: 10.1097/GCO.0b013e3280114a3a. Curr Opin Obstet Gynecol. 2007. PMID: 17218854 Review.
-
[Does molecular biology play any role in ductal carcinoma in situ?].Gynecol Obstet Fertil. 2013 Jan;41(1):45-53. doi: 10.1016/j.gyobfe.2012.11.004. Epub 2012 Dec 31. Gynecol Obstet Fertil. 2013. PMID: 23286959 French.
-
Ductal carcinoma in situ: morphology-based knowledge and molecular advances.Adv Anat Pathol. 2013 Jul;20(4):205-16. doi: 10.1097/PAP.0b013e3182976ed5. Adv Anat Pathol. 2013. PMID: 23752083 Review.
Cited by
-
Inhibition of janus kinase 2 by compound AG490 suppresses the proliferation of MDA-MB-231 cells via up-regulating SARI (suppressor of AP-1, regulated by IFN).Iran J Basic Med Sci. 2015 Jun;18(6):599-603. Iran J Basic Med Sci. 2015. PMID: 26221484 Free PMC article.
-
Aryl Hydrocarbon Receptor Diet and Breast Cancer Risk.Yale J Biol Med. 2018 Jun 28;91(2):105-127. eCollection 2018 Jun. Yale J Biol Med. 2018. PMID: 29962921 Free PMC article. Review.
-
Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings.Cureus. 2023 Jun 6;15(6):e40066. doi: 10.7759/cureus.40066. eCollection 2023 Jun. Cureus. 2023. PMID: 37425505 Free PMC article.
-
MiR-126 regulated breast cancer cell invasion by targeting ADAM9.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6547-53. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26261534 Free PMC article.
-
Diagnostic, Prognostic, and Predictive Molecular Biomarkers and the Utility of Molecular Imaging in Common Gastrointestinal Tumors.Biomed Res Int. 2015;2015:890805. doi: 10.1155/2015/890805. Epub 2015 Nov 4. Biomed Res Int. 2015. PMID: 26618179 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical